ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Expert Interviews
Can Testosterone Induce Blood Clots and Thrombosis? Interview with Dr Charles Glueck
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 9100" data-attributes="member: 3"><p>To to Dr Glueck's research, the FDA added this warning to testosterone package insert labels:</p><p></p><p><strong>FDA adding general warning to testosterone products about potential for venous blood clots</strong></p><p><strong></strong></p><p></p><p>[06/19/2014] The U.S. Food and Drug Administration (FDA) is requiring manufacturers to include a general warning in the drug labeling of all approved testosterone products about the risk of blood clots in the veins. Blood clots in the veins, also known as venous thromboembolism (VTE), include deep vein thrombosis (DVT) and pulmonary embolism (PE). The risk of venous blood clots is already included in the labeling of testosterone products as a possible consequence of polycythemia, an abnormal increase in the number of red blood cells that sometimes occurs with testosterone treatment. Because there have been postmarket reports of venous blood clots unrelated to polycythemia, FDA is requiring a change to drug labeling of all testosterone products to provide a more general warning regarding venous blood clots and to ensure this risk is described consistently in the labeling of all approved testosterone products.</p><p></p><p>Because these clots occur in the veins, this new warning is not related to FDA's ongoing evaluation of the possible risk of stroke, heart attack, and death in patients taking testosterone products. We are currently evaluating the potential risk of these cardiovascular events, which are related to blood clots in the arteries and are described in the (link removed)</p><p>Testosterone products are FDA-approved for use in men who lack or have low testosterone levels in conjunction with an associated medical condition. Examples of these conditions include failure of the testicles to produce testosterone for reasons such as genetic problems or chemotherapy.</p><p></p><p>FDA asks health care professionals and consumers to report any adverse reactions to the FDA's MedWatch Safety Information and Adverse Event Reporting program:</p><p>Complete and submit the report online at <a href="https://www.accessdata.fda.gov/scripts/medwatch/" target="_blank">MedWatch Voluntary Reporting Form</a></p><p></p><p>Download and complete the form, then submit it via fax to 1-800-FDA-0178</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 9100, member: 3"] To to Dr Glueck's research, the FDA added this warning to testosterone package insert labels: [B]FDA adding general warning to testosterone products about potential for venous blood clots [/B] [06/19/2014] The U.S. Food and Drug Administration (FDA) is requiring manufacturers to include a general warning in the drug labeling of all approved testosterone products about the risk of blood clots in the veins. Blood clots in the veins, also known as venous thromboembolism (VTE), include deep vein thrombosis (DVT) and pulmonary embolism (PE). The risk of venous blood clots is already included in the labeling of testosterone products as a possible consequence of polycythemia, an abnormal increase in the number of red blood cells that sometimes occurs with testosterone treatment. Because there have been postmarket reports of venous blood clots unrelated to polycythemia, FDA is requiring a change to drug labeling of all testosterone products to provide a more general warning regarding venous blood clots and to ensure this risk is described consistently in the labeling of all approved testosterone products. Because these clots occur in the veins, this new warning is not related to FDA's ongoing evaluation of the possible risk of stroke, heart attack, and death in patients taking testosterone products. We are currently evaluating the potential risk of these cardiovascular events, which are related to blood clots in the arteries and are described in the (link removed) Testosterone products are FDA-approved for use in men who lack or have low testosterone levels in conjunction with an associated medical condition. Examples of these conditions include failure of the testicles to produce testosterone for reasons such as genetic problems or chemotherapy. FDA asks health care professionals and consumers to report any adverse reactions to the FDA's MedWatch Safety Information and Adverse Event Reporting program: Complete and submit the report online at [URL="https://www.accessdata.fda.gov/scripts/medwatch/"]MedWatch Voluntary Reporting Form[/URL] Download and complete the form, then submit it via fax to 1-800-FDA-0178 [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Expert Interviews
Can Testosterone Induce Blood Clots and Thrombosis? Interview with Dr Charles Glueck
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top